Explore by Category
Karyopharm Launches Multiple Myeloma Drug Selinexor in COVID-19 Clinical Trial
MYELOMA NEWS - April 07, 2020
Karyopharm is launching a new trial to explore the use of the oral multiple myeloma drug selinexor (XPOVIO) as a potential therapy for hospitalized COVID-19 pat... Read More
Chinese Report: Myeloma Patient with COVID-19 Responds to Monoclonal Antibody
MYELOMA NEWS - April 06, 2020
Less than two weeks after the start of a clinical trial of tocilizumab for severe COVID-19 infection, Chinese researchers released an Exceptional Case Report in... Read More
A New and Different Approach to Treat Triple Refractory Multiple Myeloma
MYELOMA NEWS - April 02, 2020
The Swedish company Oncopeptides announced interesting news, a few days ago, for those of us who have failed prior treatment with immunomodulators and proteas... Read More
FDA Asked to Approve Use of Multiple Myeloma BMS/bluebird bio CAR T-cell Therapy
MYELOMA NEWS - April 02, 2020
More myeloma patients may soon have access to CAR T-cell therapy because Bristol-Myers Squibb (BMS) and bluebird bio applied to the U.S. Food & Drug Admin... Read More
Genentech Tests Tocilizumab (Used for Cytokine Release Syndrome in Myeloma CAR T Therapy) in Phase III Trial for Severe COVID-19
MYELOMA NEWS - March 23, 2020
Genentech is working with the FDA to launch a Phase III study comparing tocilizumab (Actemra) vs. standard of care in hospitalized adult patients with severe ... Read More
Cell Therapies for Multiple Myeloma
MYELOMA NEWS - March 12, 2020
There are literally hundreds of clinical trials underway using different cell therapies for the treatment of a variety of cancers. Most of us are aware of som... Read More
XPOVIO (selinexor) Study Shows Impact When Used in Earlier Lines of Multiple Myeloma Therapy with Velcade and Dex
MYELOMA NEWS - March 11, 2020
Using XPOVIO (selinexor) and Velcade weekly with low-dose dexamethasone showed a 47% increase in progression free survival compared to Velcade (twice weekly) ... Read More
Myeloma Crowd Pledges Support for the Interoperability Rules Finalized Today by the US Department of Health and Human Services
MYELOMA NEWS - March 09, 2020
CrowdCare Founder and Patient Advocate Jenny Ahlstrom Says Patient Access to Data is the Key to Curing Disease SALT LAKE CITY, UT – March 9, 2020 &nd... Read More
New CD38 Monoclonal Antibody Sarclisa® (isatuximab) Receives FDA Approval for Relapsed Multiple Myeloma
MYELOMA NEWS - March 02, 2020
The FDA today approved a new monoclonal antibody targeting CD38 for the treatment of relapsed and refractory multiple myeloma patients. Sarclisa® (isatuxi... Read More
Better Gut Diversity Before Allo Transplant Lowers Death Rate for Blood Cancer Patients
MYELOMA NEWS - February 28, 2020
A recent study of over 1,300 Allogeneic (donor) transplant patients with blood cancers (including multiple myeloma - 8% of the patients) showed that patients w... Read More
Myeloma Community Loses Myeloma Great, Dr. Phillip Greipp of the Mayo Clinic Rochester
MYELOMA NEWS - February 27, 2020
Philip Robert Greipp, M.D., 77, passed away Tuesday evening, Feb. 11 at Fairview Southdale Hospital in Edina, from complications of an acute illness and a previ... Read More
Making a safer CAR-T
MYELOMA NEWS - February 26, 2020
Prior posts on Myeloma Crowd have already mentioned that patients undergoing therapy with current CAR-T constructs have a good chance to experience a side eff... Read More
Natural Killer Cells to Fight Multiple Myeloma
MYELOMA NEWS - February 19, 2020
Scientific progress in treating multiple myeloma has been moving forward over the past few years at a speed not seen in the more distant past. We have become ... Read More
